Company Profile
Iovance Biotherapeutics, Inc. Stock Price, News & Analysis
- Ticker:
- IOVA
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
6.21 USD (+43.09%)
Close
Last updated: August 6, 2026
1.83B USD
Market cap
Why the stock is moving
Following the latest company update, “Iovance Biotherapeutics Reports Record Second Quarter 2026 Revenue of ~$99M, Business Achievements, and Corporate Updates”, IOVA closed up 43.1% at $6.21 on Aug 6, 2026. The move occurred in the trading session associated with this earnings update.
Company overview
Tumor-Infiltrating Lymphocyte Therapy
Iovance Biotherapeutics develops and commercializes autologous tumor-infiltrating lymphocyte therapies for solid tumors. Patient T cells are isolated from a tumor, expanded and reinfused following lymphodepletion.
Amtagvi
Amtagvi, or lifileucel, is approved in the United States for selected patients with advanced melanoma. Iovance manufactures the therapy through a centralized cell-therapy infrastructure.
Registrational Expansion
Lifileucel is being evaluated in non-small cell lung cancer, endometrial cancer and sarcoma. IOV-SAR-201 targets undifferentiated pleomorphic sarcoma and dedifferentiated liposarcoma.
Next-Generation TILs
IOV-5001 is an IL-12-tethered TIL therapy, while IOV-4001 incorporates PD-1 inactivation. These programs aim to enhance activity in immunologically resistant tumors.
Future catalysts
Australian regulatory decision for lifileucel in the first half of 2026.
Updated IOV-LUN-202 data at a major medical meeting during 2026.
Site activation and enrollment in IOV-SAR-201 in the third quarter of 2026.
Initiation of Phase 1/2 enrollment for IOV-5001 in the second half of 2026.
EMA resubmission for lifileucel during 2026 and a Swiss regulatory decision in the first half of 2027.
Recent news
- 01
Iovance Biotherapeutics Reports Record Second Quarter 2026 Revenue of ~$99M, Business Achievements, and Corporate Updates
Source: Iovance Biotherapeutics, Inc.
- 02
Iovance Biotherapeutics to Report Second Quarter 2026 Financial Results and Corporate Updates on Thursday, August 6, 2026
Source: Iovance Biotherapeutics, Inc.
- 03
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Source: Iovance Biotherapeutics, Inc.
- 04
Iovance’s Amtagvi® (lifileucel) Granted Approval for the Treatment of Advanced Melanoma in Australia
Source: Iovance Biotherapeutics, Inc.
- 05
Iovance Biotherapeutics Announces Clearance of Investigational New Drug (IND) Application for IL-12 Tethered TIL Therapy IOV-5001
Source: Iovance Biotherapeutics, Inc.
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Iovance Biotherapeutics, Inc. (IOVA)?
Iovance Biotherapeutics, Inc. (IOVA) most recently closed at 6.21 USD, a +43.09% move versus the previous session.
What is the market cap of Iovance Biotherapeutics, Inc. (IOVA)?
Iovance Biotherapeutics, Inc. currently has a market capitalization of 1.83B USD on BioPharmSignal.
What does Iovance Biotherapeutics, Inc. do?
Tumor-Infiltrating Lymphocyte Therapy Iovance Biotherapeutics develops and commercializes autologous tumor-infiltrating lymphocyte therapies for solid tumors. Patient T cells are isolated from a tumor, expanded and reinfused following lymphodepletion. Amtagvi Amtagvi, or lifileucel, is approved in the United States for selected patients with advanced...
On which exchange is IOVA stock listed?
Iovance Biotherapeutics, Inc. (IOVA) is associated with NASDAQ, United States, Biopharma.
What is IOV-SAR-201?
Site activation and enrollment in IOV-SAR-201 in the third quarter of 2026.
Which conditions is Iovance Biotherapeutics, Inc. targeting with IOV-SAR-201?
Iovance Biotherapeutics, Inc. is associated with cancer therapeutics based on its company overview and current catalyst commentary.
How does Iovance Biotherapeutics, Inc. describe recent progress with IOV-SAR-201?
Site activation and enrollment in IOV-SAR-201 in the third quarter of 2026.
What is IOV-5001?
Next-Generation TILs IOV-5001 is an IL-12-tethered TIL therapy, while IOV-4001 incorporates PD-1 inactivation.